Opendata, web and dolomites


TIGIT therapy for cancer treatment

Total Cost €


EC-Contrib. €






Project "TIGITtherapy" data sheet

The following table provides information about the project.


Organization address
postcode: 91904

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-07-01   to  2018-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Treating tumors with immune-related therapies is one of the most exciting and promising advancements made in the past decade. Cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market. TIGIT is an important checkpoint inhibitory receptor discovered by our group in 2009. It is constitutively expressed by various immune cells and its expression is further increased on tumor infiltrating lymphocytes (TILs). TIGIT recognizes two main ligands, PVR and Nectin2 that are highly expressed on various tumors. Blockage of TIGIT on TILs either alone or in combination with another checkpoint inhibitory receptor, PD-1, leads to increased T and Natural Killer (NK) cell activity in vitro and inhibited tumor growth in vivo. We developed 9 different anti-TIGIT mAbs during my BacNK ERC advanced grant and previously. In the POC grant TIGITtherapy, which already attracted interest from several bio pharma companies, I propose testing which of the 9 anti-TIGIT mAbs and TIGIT-Ig are able to antagonize TIGIT activity.


year authors and title journal last update
List of publications.
2018 Moriya Gamliel, Debra Goldman-Wohl, Batya Isaacson, Chamutal Gur, Natan Stein, Rachel Yamin, Michael Berger, Myriam Grunewald, Eli Keshet, Yoach Rais, Chamutal Bornstein, Eyal David, Adam Jelinski, Iris Eisenberg, Caryn Greenfield, Arbel Ben-David, Tal Imbar, Ronit Gilad, Ronit Haimov-Kochman, David Mankuta, Matan Elami-Suzin, Ido Amit, Jacob H. Hanna, Simcha Yagel, Ofer Mandelboim
Trained Memory of Human Uterine NK Cells Enhances Their Function in Subsequent Pregnancies
published pages: 951-962.e5, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2018.03.030
Immunity 48/5 2019-06-06
2018 Liat Dassa, Einat Seidel, Esther Oiknine-Djian, Rachel Yamin, Dana G. Wolf, Vu Thuy Khanh Le-Trilling, Ofer Mandelboim
The Human Cytomegalovirus Protein UL148A Downregulates the NK Cell-Activating Ligand MICA To Avoid NK Cell Attack
published pages: , ISSN: 0022-538X, DOI: 10.1128/jvi.00162-18
Journal of Virology 92/17 2019-06-06
2018 Dominik Schmiedel, Ofer Mandelboim
NKG2D Ligands–Critical Targets for Cancer Immune Escape and Therapy
published pages: , ISSN: 1664-3224, DOI: 10.3389/fimmu.2018.02040
Frontiers in Immunology 9 2019-06-06
2018 Tirtsah Toledano, Alon Vitenshtein, Noam Stern-Ginossar, Einat Seidel, Ofer Mandelboim
Decay of the Stress-Induced Ligand MICA Is Controlled by the Expression of an Alternative 3′ Untranslated Region
published pages: 2819-2825, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1700968
The Journal of Immunology 200/8 2019-06-06
2017 Yoav Charpak-Amikam, Tobias Kubsch, Einat Seidel, Esther Oiknine-Djian, Noemi Cavaletto, Rachel Yamin, Dominik Schmiedel, Dana Wolf, Giorgio Gribaudo, Martin Messerle, Luka Cicin-Sain, Ofer Mandelboim
Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20
published pages: , ISSN: 2045-2322, DOI: 10.1038/s41598-017-08866-2
Scientific Reports 7/1 2019-06-06
2018 Ariella Glasner, Assi Levi, Jonatan Enk, Batya Isaacson, Sergey Viukov, Shari Orlanski, Alon Scope, Tzahi Neuman, Claes D. Enk, Jacob H. Hanna, Veronika Sexl, Stipan Jonjic, Barbara Seliger, Laurence Zitvogel, Ofer Mandelboim
NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis
published pages: 107-119.e4, ISSN: 1074-7613, DOI: 10.1016/j.immuni.2017.12.007
Immunity 48/1 2019-06-06

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TIGITTHERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TIGITTHERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)


The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  


Dynamic Modeling of Labor Market Mobility and Human Capital Accumulation

Read More